Key clinical point: Emicizumab appears safe and effective for patients with hemophilia A undergoing surgical procedures.
Major finding: Out of 28 minor procedures performed without preventive factor VIII, 2 (7.1%) were associated with a bleed requiring treatment.
Study details: An analysis of 30 patients from the HAVEN 3 trial who underwent 50 surgeries.
Disclosures: Study funding was provided by F. Hoffmann–La Roche and Chugai Pharmaceutical. The investigators reported financial relationships with Bayer, Shire, Pfizer, Novo Nordisk, and others.
Santagostino E et al. EAHAD 2019, Abstract OR15.